(Q34141305)

English

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

scientific article published on October 2, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

M. Hallek

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

Pier Luigi Zinzani

13

object named as

P. L. Zinzani

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

19

object named as

M. Trneny

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

author name string

International Group of Investigators

33

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

German Chronic Lymphocytic Leukaemia Study Group

34

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

K. Fischer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

G. Fingerle-Rowson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

A. M. Fink

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

R. Busch

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

J. Mayer

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

M. Hensel

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

G. Hopfinger

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

G. Hess

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

U. von Grünhagen

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

M. Bergmann

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

J. Catalano

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

F. Caligaris-Cappio

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

J. F. Seymour

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

A. Berrebi

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

U. Jäger

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

B. Cazin

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

A. Westermann

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

C. M. Wendtner

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

B. F. Eichhorst

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

P. Staib

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

A. Bühler

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

D. Winkler

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

T. Zenz

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

S. Böttcher

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

M. Ritgen

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

M. Mendila

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

M. Kneba

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

H. Döhner

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

S. Stilgenbauer

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20888994

25 July 2024

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2 October 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20888994

25 July 2024

full work available at URL

https://api.elsevier.com/content/article/PII:S0140673610613815?httpAccept=text/xml

1 reference

10.1016/S0140-6736(10)61381-5

https://api.crossref.org/works/10.1016/S0140-6736(10)61381-5

25 July 2024

https://api.elsevier.com/content/article/PII:S0140673610613815?httpAccept=text/plain

1 reference

10.1016/S0140-6736(10)61381-5

https://api.crossref.org/works/10.1016/S0140-6736(10)61381-5

25 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

376

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9747

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1164-1174

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent developments in the treatment of aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity and functional status are independent in older cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of UnmutatedVHGene in Patients With Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961381-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia

13

1 reference

10.1016/S0140-6736(10)61381-5

https://api.crossref.org/works/10.1016/S0140-6736(10)61381-5

25 July 2024

Identifiers

10.1016/S0140-6736(10)61381-5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34141305&oldid=2212407583"